Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis

Thaweethamcharoen, Tanita; Sakulbumrungsil, Rungpetch; Nopmaneejumruslers, Cherdchai; Vasuvattakul, Somkiat

doi:10.1016/j.vhri.2014.01.001

Cited by 10 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were two common variations to this structure: first, models differed in the approach to modelling dialysis and, second, they differed on how kidney function was modelled post-transplant. Dialysis was modelled as a single health state [44, 51, 52, 55, 66, 68, 71, 74], as two separate health states for haemodialysis and peritoneal dialysis [45, 48–50, 56, 58, 62, 63, 67], as three separate health states [47, 65], or as four separate health states [43, 70] that included home haemodialysis, satellite haemodialysis, hospital haemodialysis and continuous ambulatory peritoneal dialysis [43]. Two models reported the use of five different dialysis modalities [42, 57].…”

Section: Resultsmentioning

confidence: 99%

“…In general, ESRD-only models used various forms of transition rates to model the proportion of pre-dialysis patients progressing to dialysis or transplant, as described briefly in Supplementary Tables 10–19 (Resources 5–7 of the ESM) [42–45, 47–52, 54, 56, 57, 60, 62–67, 70, 75]. These were usually derived using data obtained from national renal registries relevant to the country perspective of the model, such as the Norwegian Renal Registry [76], the UK Renal Registry [75] or the Dutch Renal Replacement Registry [77].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design

et al. 2019

View full text Add to dashboard Cite

BackgroundChronic kidney disease (CKD) is a progressive condition that leads to irreversible damage to the kidneys and is associated with an increased incidence of cardiovascular events and mortality. As novel interventions become available, estimates of economic and clinical outcomes are needed to guide payer reimbursement decisions.ObjectiveThe aim of the present study was to systematically review published economic models that simulated long-term outcomes of kidney disease to inform cost-effectiveness evaluations of CKD treatments.MethodsThe review was conducted across four databases (MEDLINE, Embase, the Cochrane library and EconLit) and health technology assessment agency websites. Relevant information on each model was extracted. Transition and mortality rates were also extracted to assess the choice of model parameterisation on disease progression by simulating patient’s time with end-stage renal disease (ESRD) and time to ESRD/death. The incorporation of cardiovascular disease in a population with CKD was qualitatively assessed across identified models.ResultsThe search identified 101 models that met the criteria for inclusion. Models were classified into CKD models (n = 13), diabetes models with nephropathy (n = 48), ESRD-only models (n = 33) and cardiovascular models with CKD components (n = 7). Typically, published models utilised frameworks based on either (estimated or measured) glomerular filtration rate (GFR) or albuminuria, in line with clinical guideline recommendations for the diagnosis and monitoring of CKD. Generally, two core structures were identified, either a microsimulation model involving albuminuria or a Markov model utilising CKD stages and a linear GFR decline (although further variations on these model structures were also identified). Analysis of parameter variability in CKD disease progression suggested that mean time to ESRD/death was relatively consistent across model types (CKD models 28.2 years; diabetes models with nephropathy 24.6 years). When evaluating time with ESRD, CKD models predicted extended ESRD survival over diabetes models with nephropathy (mean time with ESRD 8.0 vs. 3.8 years).DiscussionThis review provides an overview of how CKD is typically modelled. While common frameworks were identified, model structure varied, and no single model type was used for the modelling of patients with CKD. In addition, many of the current methods did not explicitly consider patient heterogeneity or underlying disease aetiology, except for diabetes. However, the variability of individual patients’ GFR and albuminuria trajectories perhaps provides rationale for a model structure designed around the prediction of individual patients’ GFR trajectories. Frameworks of future CKD models should be informed and justified based on clinical rationale and availability of data to ensure validity of model results. In addition, further clinical and observational research is warranted to provide a better understanding of prognostic factors and data sources to improve economic modelling accuracy in...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design

et al. 2019

View full text Add to dashboard Cite

show abstract

“…11,14,[18][19][20][21] Most HRQOL studies on dialysis patients have used KDQOL-36 measurements to evaluate the impact of dialysis on quality of life. 11,20,[22][23][24][25][26][27][28][29] As for the general questionnaires, the EQ-5D can be used to compute a utility score, which is the recommended utility tool for economic evaluations in Thailand. 30 The present study assessed the HRQOL scores of PD patients by using the KDQOL-36, the EuroQol 5-dimension 5-level questionnaire (EQ-5D-5L), and the visual analogue scale (VAS).…”

Section: Introductionmentioning

confidence: 99%

Kidney Disease–Specific Scores and Health Utility of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis Patients and Their Caregivers

Thaweethamcharoen

Noparatayaporn

Sritippayawan

et al. 2020

Value in Health Regional Issues

Self Cite

View full text Add to dashboard Cite

This study aimed to compare the EuroQol 5-dimension 5-level questionnaire (EQ-5D-5L), the visual analogue scale (VAS), and the Kidney Disease Quality of Life 36-Item Short-Form Survey (KDQOL-36) scores of Thai continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) patients and to compare the utility scores with the EQ-5D-5L and VAS scores of caregivers.Methods: This was a cross-sectional study completed between April 2016 and May 2017. In total, 34 CAPD patients, 30 APD patients, and their caregivers were recruited from a large university hospital in Thailand. A trained interviewer conducted face-to-face interviews. We collected demographic data and used the KDQOL-36 and EuroQol questionnaires (EQ-5D-5L and VAS) to assess the health-related quality of life. Caregivers were asked to assess their own health status using the EQ-5D-5L and VAS. Results:The EQ-5D-5L and VAS responses of the CAPD and APD patients and their caregivers were not significantly different (P . .05). More than 50% of both patient groups had mobility problems, whereas most patients had no problems with selfcare, doing usual activities, pain or discomfort, and anxiety or depression. As for the KDQOL-36, the physical and mental component summaries were not significantly different, and neither were the scores for all of the kidney disease-specific dimensions, including symptoms or problems, effects of kidney disease, and burden of kidney disease (all were P . .05). Conclusions:The results indicated that the quality of life of CAPD and APD patients and their caregivers were mostly equivalent. A further longitudinal study of utility score assessments of the differences in modality would be advantageous.

show abstract

“…The cost to treat anemia by rhEPO per quality-adjusted life-year was estimated at US $24,128.03 and US $28,022. 33 for the Hb level 9-10g/dl and 11-12g/dl, respectively [30]. The average GDP per capita of the global population, which was US $11570 in 2019 [31], is below the average medication cost of EPO treatment.…”

Section: Introductionmentioning

confidence: 99%

“…The high prevalence of CKD-related anemia has been creating growing demand for the rhEPO but limited supply of qualified rhEPO has made the treatment expensive. The cost to treat anemia by rhEPO per quality-adjusted life-year was estimated at US $24,128.03 and US $28,022.33 for the Hb level 9-10g/dl and 11-12g/dl, respectively [30]. The average GDP per capita of the global population, which was US $11570 in 2019 [31], is below the average medication cost of EPO treatment.…”

Section: Introductionmentioning

confidence: 99%

Development and qualification of a high-yield recombinant human Erythropoietin biosimilar

Nag¹,

Islam²,

Khan³

et al. 2023

Preprint

View full text Add to dashboard Cite

Recombinant human erythropoietin (rhEPO) has been saving millions of lives worldwide as a potent and safe treatment for the lack of erythrocyte, which is caused by chronic kidney disease (CKD) and other issues. Several biosimilars of rhEPO have been approved since the expiry of the relevant patents to provide cost-effective options but the price of rhEPO is still high for the affordability of global community. Therefore, development of biosimilar of rhEPO at a lower price is highly necessary. Here we report the development and characterization of a biosimilar of rhEPO with high-yield satisfying regulatory requirements. The hEPO-expressing cDNA was stably expressed in CHO cells with successive transfection. The master cell bank (MCB) and working cell bank (WCB) were established from the best selected clone and characterized for 50 passages. The rhEPO was expressed from the WCB in single-use suspension culture system with a high-titer (1.24 +/- 0.16 g/L). To the best of our knowledge this is the highest reported rhEPO titer to date. The rhEPO was purified using a series of validated chromatography unit processes including virus inactivation and filtration. The purified EPO was formulated in serum-free buffer, sterile filtered, and analyzed as the biosimilar of reference product Eprex(R). Physicochemical analysis strongly suggested similarities between the developed rhEPO (GBPD002) and the reference. The in vitro and in vivo functional assays confirmed the similar biofunctionality of the GBPD002 and Eprex(R). GBPD002 could provide a less-expensive solution to the needful communities as an effective and safe biosimilar where rhEPO treatment is necessary.

show abstract

Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis

Abstract: Providing EPO for a hemoglobin level of more than 10 to 11 g/dl had a cost-effectiveness higher than that of doing so for other hemoglobin levels. This finding will be put forward to the policy level to set up the EPO treatment guideline of the hospital for hemodialysis patients.

Cited by 10 publications

References 22 publications

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design

Kidney Disease–Specific Scores and Health Utility of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis Patients and Their Caregivers

Development and qualification of a high-yield recombinant human Erythropoietin biosimilar

Contact Info

Product

Resources

About